Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia Patients Have Dismal Outcomes Irrespective of Allogeneic Hematopoietic Stem Cell Transplant: A Single-Center Experience
These dismal outcomes highlight the need for development and incorporation of novel targeted agents into upfront therapy or in the post-HSCT setting for patients with this challenging disease.
Authors
- Alexandra McLean Stevens (ORCID: https://orcid.org/0000-0002-7292-2464)
- Andrea N. Marcogliese (ORCID: https://orcid.org/0000-0002-1458-9675)
- Maria Monica Gramatges (ORCID: https://orcid.org/0000-0002-0947-104X)
- Robert A. Krance (ORCID: https://orcid.org/0000-0001-7643-6933)
- Gabriela Llaurador
- Michele S. Redell (ORCID: https://orcid.org/0000-0002-2515-3703)
- Erin Doherty (ORCID: https://orcid.org/0000-0001-7720-9206)
- Swati Naik
- Matthew Willis (ORCID: https://orcid.org/0009-0001-3804-1751)
Institutions
- St. Jude Children's Research Hospital (US)
- Baylor College of Medicine (US)
- Texas Children's Hospital (US)
- Children's Cancer Center (US)
Publication Details
- Journal
- Cancers
- Published
- 2025-10-31
- DOI
- https://doi.org/10.3390/cancers17213511
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00